Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial

Chris Fox, Monica Crugel, Ian Maidment, Bjorn Henrik Auestad, Simon Coulton, Adrian Treloar, Clive Ballard, Malaz Boustani, Cornelius Katona, Gill Livingston

Research output: Contribution to journalArticlepeer-review

115 Citations (Scopus)


Agitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically significant agitation, in patients with moderate-to-severe AD.
Original languageEnglish
Article numbere35185
JournalPLoS One
Issue number5
Publication statusPublished - 2 May 2012


  • Aged
  • Aged, 80 and over
  • Alzheimer Disease
  • Dementia
  • Female
  • Humans
  • Male
  • Memantine
  • Psychomotor Agitation

Cite this